AIRWAY INFECTION

Mitra Niroumand, MD, and Ronald F. Grossman, MD, FRCPC

ACUTE BRONCHITIS

Acute bronchitis is an inflammatory condition of the tracheobronchial tree that is especially familiar to primary care physicians. As with chronic bronchitis, the definition of acute tracheobronchitis is descriptive. The original American Thoracic Society definition stressed that, in acute bronchitis, no physical or radiographic findings compatible with pneumonia could be present. In that context, acute tracheobronchitis is part of a continuum that includes nasopharyngeal infection, bronchitis, bronchiolitis, and pneumonitis. Symptomatically, these processes may be indistinguishable. Acute tracheobronchitis also implies site-specific airway inflammation between the glottis and the bronchioles.

Acute bronchitis occurs most commonly during the winter months, when acute respiratory tract infections are prevalent. The mean annual attack rate in the United States for acute bronchitis is approximately 87 cases per 100,000 persons per week, peaking in winter at approximately 150 cases per 100,000 persons per week. Acute bronchitis accounts for an estimated 12 million physician visits per year, with an annual cost of $200 million to $300 million for physician visits and prescriptions. In a national survey of more than 1500 practicing physicians in the United States, 66% of patients with the diagnosis of bronchitis were treated with antibiotics. Risk factors for increased antimicrobial prescribing were female sex and rural practice location, whereas black race was associated with a lower prescribing rate.

Etiology

The syndrome of acute bronchitis is most often associated with respiratory viruses, including common cold viruses, such as rhinovirus and coronavirus, in addition to more invasive viruses of the lower respiratory tract, such as influenza and adenovirus. Other viral causes of acute bronchitis include measles, respira-
tory syncytial virus (RSV), parainfluenza virus, and herpes simplex virus. A small proportion of cases of acute bronchitis is of nonviral etiology. Mycoplasma pneumoniae, Bordetella pertussis, and Chlamydia pneumoniae, Taiwan acute respiratory (TWAR) strain, are recognized bacterial causes of acute bronchitis. The etiologic role of Streptococcus pneumoniae and Haemophilus influenzae in acute bronchitis is not clear because these bacteria may represent resident flora of the upper respiratory tract of normal individuals. To examine the role of secondary bacterial infection in the pathogenesis of acute bronchitis, it is necessary to obtain samples from tracheobronchial trees without contamination by nasopharyngeal flora.

Acute tracheobronchitis may also be a consequence of the inhalation of irritating, toxic substances as a result of air pollution or occupational exposures to ammonia, chlorine, sulfur dioxide, nitrogen dioxide, or ozone.

**Pathogenesis**

During acute bronchial infection, the mucous membrane of the tracheobronchial tree is hyperemic and edematous, with increased bronchial secretion being a common feature. Although extensive destruction of the respiratory epithelium may be seen with influenza, other viral agents, such as rhinovirus, cause minimal epithelial injury. Impaired mucociliary function is seen in patients with all infections, even in those without overt mucosal damage. Determining the pathogenesis of acute tracheobronchitis is complicated by several factors. Studies seeking an infectious cause frequently fail to isolate a specific pathogen. A delay in seeking medical care after the onset of symptoms, which may bring the patient to medical attention beyond the period of viral shedding, may be one explanation. Determination of a causative agent is further complicated in patients with chronic lung diseases who may have tracheobronchial colonization by potentially pathogenic bacteria, including H. influenzae, S. pneumoniae, and Moraxella catarrhalis. An increase in serum antibody titers to bacteria associated with acute bronchitic symptoms suggests that bacteria may have a causative role, although analysis of antibody coating of bacteria in sputum is not helpful. In addition, severity of attacks of acute bronchitis may be increased by exposure to cigarette smoke and air pollutants. These substances in association with recurrent acute bronchial infection may result in permanent injury to the bronchial tree. Some epidemiologic studies support the potential role of acute respiratory infections in the pathogenesis of chronic obstructive lung disease. The relationship between acute bronchitis and heightened airway reactivity has also been studied extensively. Increased airway reactivity and airway resistance, usually manifested as a bothersome cough, may persist for 6 to 8 weeks. The elevated airway resistance observed after a bronchial infection is largely reversible with β-sympathomimetic and anticholinergic bronchodilators.

**Clinical Presentation**

Cough is uniformly found in patients with acute bronchitis, and it may be productive of mucoid or purulent sputum. The cough may be accompanied by variable amounts of hemoptysis or retrosternal pain that is often described as a burning sensation. It is usually accentuated on inspiration. Generally, the temperature is only minimally to moderately elevated. Physical examination often shows harsh breath sounds, rhonchi, and variable amounts of expiratory wheezing. Occasionally, focal areas of diminished breath sounds are present, which
suggest that inspissated mucus has caused atelectasis. Atelectasis may be relieved by the use of humidifiers; bronchodilators; vigorous coughing; and, if needed, tracheal suction. Sometimes, diffuse diminution of air intake or inspiratory stridor is present. These findings indicate obstruction of major bronchi or the trachea. Most viral acute tracheobronchitis runs a benign, self-limited course. However, herpes simplex type 1 has been associated with severe febrile tracheobronchitis and respiratory failure in "normal," immunocompetent adults.\textsuperscript{104}

**Diagnosis**

Bronchitis may be suspected in patients with an acute respiratory tract infection associated with cough; however, bronchitis must be considered a diagnosis of exclusion because more serious diseases of the lower respiratory tract are associated with cough. A complete history should include information on exposure to toxic substances and cigarette use, epidemiologic considerations, and vaccination history. A thorough physical examination is essential to exclude other causes of cough, including cardiovascular and parenchymal lung diseases. Routine bacterial cultures of expectorated sputum are not helpful because of the sampling problem of contamination by nasopharyngeal flora and the usual technical difficulties with collecting, transporting, and interpreting an adequate lower respiratory tract sample. Occasionally, the nature of sputum may provide some diagnostic clues. For instance, except for adenovirus infections, the sputum in viral infections almost always shows a marked predominance of mononuclear cells on Gram or Wright's stain. In contrast, in bacterial infections, the sputum shows a predominance of polymorphonuclear leukocytes. Mycoplasma infections are usually associated with mononuclear cells, but a predominant polymorphonuclear cell population may be present. Culture methods and a microimmunofluorescence test have been developed for the laboratory diagnosis of \textit{C. pneumoniae}. The use of a gamma M immunoglobulin (IgM)-specific conjugate helps detect current infection. Patients in whom cough persists beyond the expected duration of the acute illness should have further diagnostic examination, including chest radiography, sputum cytology, and bronchoscopy, to exclude other diseases of the tracheobronchial tree and lungs.

**Treatment**

In most cases of acute bronchitis, only symptomatic treatment is needed; however, patients with underlying chronic cardiopulmonary diseases who contract influenza or other severe forms of bronchitis may develop serious symptoms requiring hospitalization, oxygen therapy, and ventilatory assistance. Cough suppressants, adequate hydration to prevent drying of bronchial secretions, and symptomatic treatment of mild fever and malaise associated with some influenza-like syndromes is the cornerstone of treatment of acute bronchitis in otherwise healthy individuals. If bronchospastic symptoms are dominant, there may be a role for inhaled $\beta_2$-adrenergic bronchodilators.

The value of antibiotics in the treatment of otherwise healthy individuals with acute bronchitis has not been established, and the use of these agents is not recommended as a general practice. This uncertainty stems from conflicting results of clinical trials, which may be explained based on variations in type of antibiotics, dosage schedule, duration of follow-up, the season of the year (reflecting prevalence of different pathogens), and lack of a placebo-controlled
design in many of these studies. Factors that may prompt the use of antibiotics include patient’s age, significant underlying medical illnesses, and severe or persistent (e.g., > 1 week in duration) symptoms. Under these circumstances, treatment with tetracycline or a macrolide to cover the suspected pathogens, *M. pneumoniae*, *C. pneumoniae*, and *S. pneumoniae*, should be considered. During epidemics known to be caused by influenza A virus, treatment with amantadine is recommended for patients with suspected influenza if the illness is less than 48 hours in duration.

**ACUTE EXACERBATION OF CHRONIC BRONCHITIS**

Chronic obstructive lung disease afflicts 20% of the population and is the fourth leading cause of death in the United States. Acute bronchitis and acute exacerbation of chronic bronchitis (AECB) are frequently encountered by general and family physicians, accounting for approximately 14 million physician visits per year. Chronic bronchitis, airflow obstruction, or both were found in 14% of men and 8% of women in Tecumseh, Michigan, in a population-based survey. In the United Kingdom, one fourth of all primary care visits are related to respiratory disease, and more than half of these are caused by upper and lower respiratory tract infections. Bronchitis is associated with 28 million lost working days and 5% of deaths per year in the United Kingdom. In 1992, approximately 12 million prescriptions were given for lower respiratory tract infections, accounting for £47.2 million ($78.3 million) in expenditures. In Europe, more than 80% of all lower respiratory tract infections are treated with antibiotics. Most physicians do not differentiate acute bronchitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and viral respiratory tract infections. The pattern of antibiotic prescribing for these infections varies from country to country, but there is rationale for these antimicrobial choices exists.

Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by reduced expiratory airflow that is relatively stable over several months of observation. Chronic bronchitis is defined clinically as excessive cough, with productive of sputum on most days, for at least 3 months during at least 2 consecutive years. The major risk factor for chronic bronchitis is cigarette smoking, and cumulative smoking history is most closely related to symptom development. Other factors implicated in the development of chronic bronchitis include occupational and environmental exposures (e.g., dust, air pollution, sulfur dioxide, or nitrogen dioxide) and childhood respiratory tract infection. Passive smoking may also be a risk factor for chronic bronchitis, but the evidence to suggest this is less clear. The prognosis of COPD is affected most when lung function as reflected by the forced expiratory volume in 1 second (FEV₁) falls below 50% of predicted values. When the FEV₁ falls below 1 L, the 5-year survival rate is approximately 50%. Very poor correlation exists between the amount of sputum produced and the degree of airflow obstruction. Frequent acute exacerbations of bronchitis have not been associated with an accelerated decline in FEV₁.

**Role of Bacterial Infection**

An acute exacerbation of chronic obstructive lung disease is usually defined as an episodic respiratory decompensation without an objectively documented cause, such as pneumonia. The role of bacterial infection in acute exacerbation
of chronic bronchitis is controversial. Many patients are treated with antibiotics, but whether this treatment is efficacious is debatable. Several groups have demonstrated increased numbers of bacteria and neutrophils in sputum during exacerbations. A causal relationship can be inferred by the appearance of an acute antibody response in serum to these bacteria and an increase in inflammatory mediators in purulent sputum. The relationship between bacterial infection and symptoms is complicated by a high spontaneous remission rate; this can be expected because bacterial exacerbations are usually limited to the bronchial mucosa. In a landmark study, Anthonisen and co-workers demonstrated for the first time that patients could be stratified according to symptoms to predict a response to antimicrobial therapy. In patients with at least two of increased dyspnea, sputum volume, and sputum purulence, broad-spectrum antibiotics (e.g., amoxicillin, trimethoprim-sulfamethoxazole, or doxycycline) lead to improved clinical outcomes, fewer therapeutic failures, and a more rapid rate of lung function recovery compared with placebo. Overall, the length of illness was 2 days shorter for the antibiotic-treated group compared with the group receiving placebo. A meta-analysis of nine randomized, placebo-controlled trials of patients treated with antibiotics for acute exacerbations of chronic bronchitis concluded that a small but statistically significant clinical and physiologic improvement could be expected in antibiotic-treated patients. Table 1 demonstrates the results in seven of the nine trials and a recently completed,Table 1. SUMMARY OF RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIALS EXAMINING THE ROLE OF ANTIMICROBIAL THERAPY IN ACUTE EXACERBATION OF COPD

| Comparators                  | No. of Patients | Outcome of Therapy                                                                 | Reference                  |
|------------------------------|-----------------|-----------------------------------------------------------------------------------|----------------------------|
| Placebo versus oxytetracycline | 37              | Treated patients lost half as much time from work, and exacerbations were shorter  | Elmes et al, 1957         |
|                              | 37              |                                                                                   |                            |
| Placebo versus oxytetracycline | 27              | Treated patients recovered sooner and deteriorated less often                      | Berry et al, 1960         |
|                              | 26              |                                                                                   |                            |
| Placebo versus ampicillin     | 28              | No significant difference in clinical response                                     | Elmes et al, 1965         |
|                              | 28              |                                                                                   |                            |
| Placebo versus physiotherapy versus chloramphenicol | 10 | No significant differences in clinical outcome                                      | Peterson et al, 1967     |
|                              | 10              |                                                                                   |                            |
| Placebo versus chloramphenicol | 86              | Antibiotic therapy superior to placebo but no differences in clinical outcome between antibiotics | Pines et al, 1972        |
| Placebo versus tetracycline   | 84              |                                                                                   |                            |
| Placebo versus co-trimoxazole, amoxicillin, or doxycycline | 180 | 55% versus 68% success *(p < 0.01)*                                               | Anthonisen et al, 1987   |
| Placebo versus co-amoxiclav   | 182             |                                                                                   |                            |
| Placebo versus co-trimoxazole, amoxicillin, or doxycycline | 179 | 50.3% versus 86.4% success *(p < 0.01)*                                           | Allegra et al, 1991      |
| Placebo versus co-amoxiclav   | 190             |                                                                                   |                            |
large, randomized, placebo-controlled Italian trial that was not included in the meta-analysis. A beneficial impact of antibiotics was demonstrated in studies that included the largest number of patients. In the six trials that reported peak expiratory flow rates, an improvement of 10.75 L/min favoring the antibiotic group was noted. Although this improvement is small, it may be clinically relevant, particularly in patients with limited respiratory reserve. Design flaws in the earlier studies, such as small number of study patients, unclear selection criteria, uncertain microbiology, nonstandard evaluation criteria, and lack of stratification of patients, may account for the discrepancy in outcomes.

**Bacterial Pathogens**

Bacterial pathogens can be isolated from sputum in 50% to 60% of patients having an AECB, with *H. influenzae* being the most commonly isolated organism from sputum (Table 2). *Haemophilus parainfluenzae*, *S. pneumoniae*, and *M. catarrhalis* are also found frequently. Studies utilizing the protected specimen brush technique, in which lower respiratory tract samples are not contaminated with oropharyngeal flora, have confirmed the important role in ACEB for bacterial pathogens. Organisms associated with acute exacerbations are similar (e.g., *H. influenzae*, *H. parainfluenzae*, *S. pneumoniae*, or *M. catarrhalis*), but quantitative cultures indicate a greater number of organisms. The log colony count of organisms is of the same magnitude associated with ventilator-associated pneumonia, suggesting a significant bacterial load. Exacerbations can be caused by endogenous or exogenous reinfection by *H. influenzae*. Persistently infected patients keep the same *H. influenzae* strain for longer periods, and antibiotic therapy may not be effective in eradicating *H. influenzae*. In patients with AECB, there appears to be a relationship between severity of the underlying pulmonary disease and sputum bacteriology. Eller and co-workers have observed, that with declining lung function, prevalence of enteric gram-negative organisms and pseudomonas increases. *H. parainfluenzae* has been isolated from sputum in as many as 41% of patients with acute exacerbation of chronic bronchitis. Colony counts as high as 9.6 \( \times 10^8 \) cfu/mL in sputum cultures and a serum antibody response suggest a potential role for this organism as a true respiratory pathogen. \( \beta \)-lactamase mediated amoxicillin resistance is seen in 20% to 40% of *H. influenzae* strains in North America and Europe and in almost 100% of *M. catarrhalis* strains. In a United States survey conducted between

| Reference          | No. of Isolates | *Haemophilus influenzae* | *Moraxella catarrhalis* | *Streptococcus pneumoniae* |
|--------------------|-----------------|--------------------------|-------------------------|---------------------------|
| Davies et al, 1986  | 127             | 58.5                     | 15.0                    | 16.5                      |
| Basran et al, 1990  | 60              | 43.3                     | 3.3                     | 25.0                      |
| Chodosh, 1992      | 214             | 37.9                     | 22.4                    | 22.4                      |
| Aldons, 1991       | 53              | 70.0                     | 13.0                    | 15.0                      |
| Bachand, 1991      | 84              | 30.0                     | 10.7                    | 21.4                      |
| Lindsay et al, 1992| 398             | 49.7                     | 19.0                    | 17.0                      |
| Neu and Chick, 1993| 84              | 46.4                     | 28.6                    | 25.0                      |
1992 and 1993, 30% of all *H. influenzae* isolates were β-lactamase producing, although a few β-lactamase-negative, ampicillin-resistant strains were isolated. Of almost 700 strains of *M. catarrhalis*, β-lactamase production was found in 92%. Of nearly 800 isolates of *S. pneumoniae*, 15% demonstrated intermediate susceptibility to penicillin, whereas 7% were penicillin resistant (MIC > 2.0 μg/mL).

In a more recent survey conducted between 1994 and 1995, 36.4% of *H. influenzae* strains produced β-lactamase. Another 2.5% of *H. influenzae* isolates were β-lactamase-negative but ampicillin resistant. β-lactamase-producing *M. catarrhalis* increased to 95.3% of all isolated strains, while the overall frequency of penicillin-resistant *S. pneumoniae* increased to 23.6%. Overall, 14.1% of *S. pneumoniae* isolates demonstrated intermediate resistance, while 9.5% demonstrated high-level resistance. Of concern was the observation that 9.1% of strains demonstrated multiple drug resistance.

**Pathogenesis of Bronchial Infections**

Cigarette smoking is the most common cause of chronic bronchitis. The mucociliary system forms a primary defense mechanism of the respiratory tract against all inhaled particles, including bacteria. Viral infection and cigarette smoke frequently damage ciliated epithelium, which, in turn, impairs mucociliary clearance. Mucociliary function may also be reduced by increased mucous volume, and altered mucous rheology. Viral infections result in the release of inflammatory mediators, such as kinins, increasing local permeability that may predispose the respiratory mucosa to bacterial colonization. Loss of large areas of ciliated epithelium occurs during viral and bacterial infections and contributes to impaired mucociliary clearance. Delayed mucociliary clearance affords bacteria the opportunity to multiply and attach, first to mucous and then to mucosal surfaces. An organism that is uniquely designed to take advantage of this is nontypable *H. influenzae*. It expresses pili, and piliated isolates of nontypable *H. influenzae* adhere to human nasopharyngeal epithelial cells very well. Organisms such as *H. influenzae* produce substances that impair ciliary function, stimulate mucous production, destroy local immunoglobulins, impair phagocytic function, and damage the tracheobronchial epithelium. *H. influenzae* synthesizes histamine and releases an uncharacterized factor which impairs human neutrophil function. When these bacteria loiter in the airways, a host inflammatory response is stimulated. With the movement of large numbers of neutrophils and their subsequent release of proteinases and toxic oxygen radicals, mucous production and epithelial surface damage may be enhanced. The neutrophils are attracted by chemoattractant bacterial products. Proteinase enzymes, such as elastase, are released from neutrophils and can be found in the sputum of patients with chronic bronchitis. Progressive airway damage may occur from the products of the bacteria themselves or from the host response to these bacteria. Local host defense may be further impaired, leading to an ever-greater chance of bacterial colonization and thus further damage. This process has been termed the *vicious circle hypothesis* and may account for the insidious progression of airway disease.

**Risk Stratification**

Patients with significant compromise of lung function may develop acute respiratory failure as a consequence of an acute exacerbation. Therefore, it is...
prudent to identify this high-risk population for which an aggressive approach can be applied from the outset, hoping to avoid this important complication. Mechanical ventilation is required in 20% to 60% of these patients, and long and expensive intensive care unit (ICU) care and hospital mortality rates of 10% to 30% have been reported. Factors reported to be associated with in-hospital mortality include age of more than 65 years, comorbid respiratory and nonrespiratory organ dysfunction, and hospital length of stay before ICU admission. Patient age and severity of airway obstruction in patients with COPD were identified as the major determinants of survival in patients followed for 3 years after discharge from the hospital.

Other factors linked to survival are performance status and use of oral corticosteroids. Following institution of antibiotic therapy for an acute exacerbation of chronic bronchitis, factors predicting failure of initial antimicrobial therapy (return to the prescribing physician for more treatment) or need for hospitalization include coexistent cardiopulmonary diseases and the number of previous exacerbations. The presence of cardiovascular comorbidity and more than four exacerbations in the previous year has a sensitivity of 75% and specificity of 47% in predicting return to the prescribing physician for further treatment. Advanced age, significant impairment of lung function, poor performance status, comorbid conditions, and history of previous frequent exacerbations requiring systemic corticosteroid medications characterize a high risk group of patients. Because the cost of failure of treatment of these patients is high, an aggressive approach to treatment of this high-risk group may improve outcome. Routine antimicrobial therapy fails in 13% to 25% or more of exacerbations. Therapeutic failure leads to increased cost of care because of extra physician visits, further diagnostic tests, and repeated courses of antibiotics. It may also lead to more hospitalizations and prolonged absence from work. Stratification of patients into risk categories may allow the physician to select targeted antimicrobial therapy to prevent some of these consequences. This approach has become increasingly more important because of increasing rates of resistance to standard antimicrobial therapy. Several stratification schemes have been proposed to improve initial antimicrobial selection.

Balter and co-workers in Canada suggested that patients could be categorized into five groups (Table 3). Group 1 had acute simple bronchitis, likely viral induced, with no previous respiratory problems. Antimicrobial therapy was not recommended for this group. In patients with persistent symptoms (>1 week in duration), a macrolide to treat the suspected pathogens, M. pneumoniae, C. pneumoniae, and S. pneumoniae, was recommended. Group 2 patients had simple chronic bronchitis with minimal or no impairment of pulmonary function and without any other risk factors. Treatment was recommended because Anthonisen and co-workers demonstrated a beneficial effect of antibiotics. An aminopenicillin was suggested as first-line therapy for an acute exacerbation because the consequences of a treatment failure were expected to be relatively few. Group 3 patients were described as having moderate to severe chronic bronchitis. They may be elderly (>65 years), and were likely to have frequent exacerbations (four or more/year). Treatment with antibiotics directed toward β-lactamase-producing strains of H. influenzae and M. catarrhalis, such as a second- or third-generation cephalosporin, trimethoprim-sulfamethoxazole, amoxicillin-clavulanic acid, second-generation macrolide, or quinolone was suggested. Group 4 was similar to group 3 but had other significant comorbid illness, such as congestive heart failure, diabetes mellitus, chronic renal failure, or chronic liver disease. Treatment regimens similar to those suggested for group 3 were advised. Group 5 patients were classified as having bronchiectasis.
Table 3. PROPOSED PATIENT STRATIFICATION BY BALTER ET AL.16

| Category | Characteristics                                                                 | Suggested Treatment                      |
|----------|---------------------------------------------------------------------------------|------------------------------------------|
| Group 1  | Acute simple bronchitis; no previous respiratory problems                        | No treatment                             |
|          |                                                                                 | Macrolide for persistent symptoms        |
| Group 2  | Simple chronic bronchitis; little or no lung impairment; no other risk factors   | Aminopenicillin                           |
| Group 3  | Moderate–severe chronic bronchitis; elderly (>65 years of age); ≥ 4 exacerbations/year | Second- or third-generation cephalosporin |
|          |                                                                                 | TMP/SMX                                   |
|          |                                                                                 | Amoxicillin-clavulanic acid               |
|          |                                                                                 | Second-generation macrolide               |
|          |                                                                                 | Fluoroquinolones                          |
|          |                                                                                 | Similar to group 3                        |
| Group 4  | Similar to group 3, plus significant comorbid illnesses: CHF, diabetes mellitus, chronic renal failure, chronic liver disease | According to sputum culture              |
| Group 5  | Bronchiectasis                                                                  |                                          |

Sputum cultures were recommended for this group to tailor therapy to the isolated pathogen.

Lode proposed patients be divided into three groups72 (Table 4). "First-degree" patients were defined as those with a relatively short duration of chronic bronchitis; rare exacerbations; normal lung function; and infection with the usual pathogens, namely, *H. influenzae* and *S. pneumoniae*. The suggested antimicrobial choices for this group included oral amoxicillin, doxycycline, co-trimoxazole, or a macrolide. "Second-degree" patients were defined as having a longer history of chronic obstructive lung disease, several exacerbations each year, and impaired lung function. Because of the concern of gram-negative pathogens, Lode

Table 4. STRATIFICATION SCHEME SUGGESTED BY LODE72

| Category       | Characteristics                                                                 | Suggested Treatment                      |
|----------------|---------------------------------------------------------------------------------|------------------------------------------|
| First degree   | Short history of symptoms; rare exacerbations; normal lung function              | Amoxicillin                              |
|                |                                                                                 | Doxycycline                              |
|                |                                                                                 | Co-trimoxazole                           |
|                |                                                                                 | Macrolide                                |
| Second degree  | Longer history of COPD; several exacerbations/year; impaired lung function       | Cephalosporins                           |
|                |                                                                                 | Amoxicillin-clavulanic acid              |
|                |                                                                                 | Fluoroquinolones                         |
| Third degree   | Hospitalized patient with significant comorbidity; prolonged history of COPD;    | Cephalosporins                           |
|                | severe functional impairment; frequent infections with gram-negative pathogens    | Amoxicillin-clavulanic acid              |
|                |                                                                                 | Fluoroquinolones                         |
|                |                                                                                 | Aminoglycosides                          |
|                |                                                                                 | β-lactams intravenously                   |

COPD, chronic obstructive pulmonary disease.
proposed the use of oral cephalosporins, amoxicillin-clavulanic acid, or quinolones. "Third-degree" patients were described as hospitalized patients with significant comorbidity, prolonged history of COPD, severe functional impairment, and frequent infections with gram-negative pathogens. He suggested oral therapy with cephalosporins, amoxicillin-clavulanic acid, or quinolones. In hospitalized patients, these same drugs, administered intravenously or an aminoglycoside in combination with β-lactam antibiotic, were recommended.

In the United Kingdom, Wilson118 classified patients into four groups (Table 5). Group 1 patients have acute bronchitis that is usually viral in origin. Because no underlying lung disease is present in this group, the illness is usually self-limited and runs a benign course. Group 2 patients have simple chronic bronchitis, are younger, have only mild to moderate impairment of lung function (FEV1 > 50% predicted value) and have less than four exacerbations per year. In this group of patients, typical pathogens, including H. influenzae, S. pneumoniae, and M. catarrhalis are present, although viral infection often precedes bacterial superinfection. Treatment with a β-lactam is usually successful, and the prognosis is excellent. Group 3 patients are older and may have poor underlying lung function (FEV1 < 50% predicted). Alternatively, they may demonstrate only moderate impairment of lung function (FEV1 50%-65% predicted) but have significant comorbidity (e.g., diabetes mellitus, congestive heart failure, chronic renal disease, or chronic liver disease) or, experience four or more exacerbations per year. H. influenzae, S. pneumoniae, and M. catarrhalis continue to be the predominant organisms. In this group of patients, initial treatment failure has major implications for the patient and health-care system, including increased time lost from work, hospitalization, or both. Treatment with medications directed toward resistant organisms, such as a quinolone, amoxicillin-clavulanic acid, second- or third-generation cephalosporins, or a second-generation macrolide should perform better than amoxicillin. Group 4 patients suffer from chronic bronchial infection with frequent exacerbations characterized by increased spu-

| Category | Characteristics | Suggested Treatment |
|----------|-----------------|---------------------|
| Group 1  | Postviral tracheobronchitis; previously healthy person | None |
| Group 2  | Simple chronic bronchitis; young person; mild–moderate impairment of lung function (FEV1 > 50% predicted); < 4 exacerbations/year | β-lactam antibiotics |
| Group 3  | "Chronic bronchitis plus" older person; FEV1 <50% predicted or FEV1 50%-60% predicted but concurrent medical illnesses; CHF; diabetes mellitus, chronic renal disease, chronic liver disease, >4 exacerbations/year | Fluoroquinolones Amoxicillin-clavulanic acid Second- or third-generation cephalosporins Second-generation macrolide |
| Group 4  | "Chronic bronchial sepsis," bronchiectasis, chronic airway colonization | Tailor antimicrobial treatment to airway pathogens |

FEV1, forced expiratory volume in 1 second; CHF, congestive heart failure.
tum production, increased sputum purulence, cough, and worsening dyspnea. Many of these patients have evidence of bronchiectasis if subjected to high-resolution CT scanning. These individuals tend to have a chronic progressive course, and an aggressive therapeutic approach should be offered. In addition to the usual respiratory organisms, other gram-negative organisms, including Enterobacteriaceae and *Pseudomonas* spp., should be considered as potential pathogens. Ciprofloxacin is the agent with the most activity against these species and should be considered the agent of choice when they are identified.  

These and other classification systems emphasize identifying the high-risk population so they can be treated, from the outset, with antibiotics designed to deal with potential resistant organisms. This approach may reduce risk for treatment failure, which, especially in high-risk population, has significant medical and economical implications.

In a recently completed study, patients with at least three treated exacerbations in the past year (class 3 patients) were randomized to receive either ciprofloxacin or any non-quinolone-based therapy for their next acute exacerbation of chronic bronchitis. In this prospective health economic study, clinical endpoints (i.e., days of illness, hospitalizations, and time to next exacerbation) were blended with quality-of-life measurements (Nottingham Health Profile, St. George’s Hospital Respiratory Questionnaire, Health Utility Index) and total respiratory costs from a societal perspective. Although the overall results indicated no preference for either treatment arm, in patients with risk factors (i.e., severe underlying lung disease, more than four exacerbations/year, duration of bronchitis > 10 years, elderly, or significant comorbid illness), the use of ciprofloxacin led to improved clinical outcome, higher quality of life, and lower costs. The results of this study suggest that aggressive antimicrobial therapy directed especially toward resistant organisms in high-risk patients may be a more effective strategy than no therapy or therapy with older antimicrobials that are not effective particularly against β-lactamase–producing *H. influenzae*.

**Nonantimicrobial Treatment**

Treatment of acute exacerbation of chronic bronchitis falls into two general approaches of preventive and symptomatic therapies.

**Preventive Measures**

Smoking cessation has been identified as a major cornerstone of management of patients with chronic bronchitis. The recent Lung Health Study confirmed that smoking cessation greatly reduces the rate of decline of FEV1. The benefit of smoking cessation is seen even in patients over the age of 60 years. Chronic sputum production often clears within 4 weeks of smoking cessation. Nicotine-replacement therapy is an effective approach to smoking cessation, although counseling by a physician has been shown to be the most potent intervention.

Annual influenza vaccination reduces morbidity and mortality of influenza in the elderly by 50%. This beneficial effect is believed to be the result of prevention of airway epithelial damage predisposing to subsequent bacterial infection caused by the virus. The beneficial effect of pneumococcal vaccine in patients with chronic bronchitis has not been firmly established; however, current recommendations are that patients with COPD receive Pneumovax (23 valent pneumococcal vaccine) at least once in their lives and considerations be
given to repeating the vaccine every 5 to 10 years, especially in high-risk patients or those that have a rapid decline in pneumococcal antibody levels.\textsuperscript{4, 64}

Orcel and co-workers\textsuperscript{88} showed a 40\% reduction in the incidence of acute exacerbation of chronic bronchitis after oral immunization with lyophilized fractions of the eight most common pathogens isolated in respiratory tract infections.\textsuperscript{88} This was a randomized, double-blind, placebo-controlled trial. At the present time, however, oral vaccination for patients with chronic bronchitis remains an experimental approach.

\textit{Symptomatic Therapy}

Generally a combination of inhaled anticholinergic with inhaled \( \beta \)-agonist is used in the treatment of acute exacerbation of chronic bronchitis. Oxygen therapy to maintain a \( \text{PO}_2 \) of more than 60 mm Hg or an arterial oxygen saturation of more than 90\% may be required. Excessive use of oxygen should be avoided because it may lead to progressive hypercapnia, either by decreasing hypoxic ventilatory drive or by worsening ventilation-perfusion mismatching within the lung.

Aminophylline in acute exacerbation of chronic bronchitis adds little to the bronchodilating potential of inhaled medications and increases side effects.\textsuperscript{95} Retrospective reviews of patients presenting to the emergency room with acute exacerbation of COPD show a clear benefit in the group treated with corticosteroids.\textsuperscript{95} Albert and co-workers\textsuperscript{2} reported faster improvement of pulmonary function tests in a randomized, placebo-controlled, double-blind clinical trial of parenteral corticosteroids during acute exacerbations of COPD.\textsuperscript{2} The results of the current Systemic Corticosteroids in COPD Exacerbation (SCCOPE) clinical trial being conducted by the Veterans' Affairs Medical Research Service will better define the role for oral corticosteroids. Currently, the weight of clinical evidence supports use of a course of systemic corticosteroids in the management of acute exacerbation of chronic bronchitis.

\textbf{SUMMARY}

Bronchitis in its acute and chronic forms with recurrent acute exacerbations is one of the most common reasons for physician visits, accounting for a significant cost to the health-care system, lost work days, and increased morbidity and mortality. Smoking and recurrent lower respiratory tract infections are major risk factors for chronic bronchitis. Therefore, smoking cessation and vaccination strategies are cornerstones of management in terms of halting disease progression and reducing the frequency of infectious exacerbations. Bacterial infection is the main culprit in acute flares of the disease. Routine antimicrobial therapy fails in a significant number of patients, and therapeutic failures lead to increased costs. Several stratification schemes have been proposed to improve initial antimicrobial selection. These schemes identify patient's age, severity of underlying pulmonary dysfunction, frequency of exacerbations, and the presence of comorbid illnesses as predictors for likely pathogens and to guide antimicrobial selection. This approach may reduce the risk for treatment failure, which would have significant medical and economic implications. Improved understanding of the roles of airway inflammation and infection in the pathogenesis of progressive airway disease, in addition to future studies examining the efficacy of newer classes of antimicrobials, should guide physicians to target early and effective treatment to high-risk patients.
References

1. Adler KB, Hendley DD, Davis GS: Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 125:501–514, 1986
2. Albert RK, Martin TR, Lewis SW: Controlled trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 92:753–758, 1980
3. Aldons PM: A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 27(Suppl A):101–108, 1991
4. Allegra L, Grassi C, Grossi E, et al: Ruolo degli antibiotici nel trattamento delle riacutizzata della bronchite cronica. Ital J Chest Dis 45:138–148, 1991
5. American Thoracic Society: Definitions and classifications of infectious reactions of the lung. Am Rev Respir Dis 101:119, 1970
6. American Thoracic Society: Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136:225–244, 1987
7. Amitani R, Wilson R, Rutman R, et al: Effects of human neutrophil elastase and Pseudomonas aeruginosa proteases on human respiratory epithelium. Am J Respir Cell Mol Biol 4:26–32, 1991
8. Anthonisen NR, Connett JE, Kiley JP, et al: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 272:1497–1505, 1994
9. Anthonisen NR, Manfreda J, Warren CPW, et al: Antibiotic therapy in exacerbations of chronic obstructive lung disease. Ann Intern Med 106:196–204, 1987
10. Anthonisen NR, Wright EC, Hodgkin JE, and IPPB Trial Group: Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 133:14–20, 1986
11. Apicella MA, Shero M, Dudas KC, et al: Fimbriation of Hemophilus species isolated from the respiratory tract of adults. J Infect Dis 150:40–43, 1984
12. Ayres JG: Seasonal pattern of acute bronchitis in general practice in the United Kingdom. Thorax 41:106–110, 1986
13. Bachand RT Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 27(Suppl A):91–100, 1991
14. Bakaletz LO, Tallan BM, Hoepf T, et al: Frequency of fimbriation of nontypable Hemophilus influenzae and its ability to adhere to chinchilla and human respiratory epithelium. Infect Immun 56:331–335, 1988
15. Ball P, Harris JM, Lowson D, et al: Acute infective exacerbation of chronic bronchitis. Q J Med 88:61–68, 1995
16. Baier MS, Hyland RH, Low DE, et al: Recommendations on the management of chronic bronchitis. Canadian Medical Association Journal 151(suppl):7–23, 1994
17. Barry AL, Pfaller MA, Fuchs PC, et al: In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 38:2419–2425, 1994
18. Basran GS, Joseph J, Abbas AMA, et al: Treatment of acute exacerbations of chronic obstructive airways disease: A comparison of amoxicillin and ciprofloxacin. J Antimicrob Chemother 26 Suppl F:19–24, 1990
19. Bates DV: The fate of chronic bronchitis: A report of ten year follow-up in the Canadian Department of Veterans’ Affairs coordinated study of chronic bronchitis. Am Rev Respir Dis 108:1043–1065, 1973
20. Berry DG, Fry J, Hindley CP, et al: Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1:137–139, 1960
21. Burrows B, Lebowitz MD: Quantitative relationship between cigarette smoking and chronic productive cough. Int J Epidemiol 6:107–113, 1977
22. Boldy DAR, Skidmore SJ, Ayres JG: Acute bronchitis in the community: Clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine. Respir Med 84:377–385, 1990
23. Burge PS: Occupation and chronic obstructive pulmonary disease (COPD). Eur Respir J 7:1032–1034, 1994
24. Butler JC, Breinan RF, et al: Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendation. JAMA 270:1826–1831, 1993
25. Camner P, Jarstrand C, Philipson K: Tracheobronchial clearance in patients with influenza. Am Rev Respir Dis 108:131–135, 1973
26. Chodosh S: Acute bacterial exacerbations in bronchitis and asthma. Am J Med 82(Suppl 4A):154–163, 1987
27. Chodosh S: Bronchitis and asthma. In Gorbach SL, Bartlett JG, Blacklow NR (eds): Infectious Diseases. Philadelphia, WB Saunders, 1992, pp 476–485
28. Chodosh S: Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am J Med 91(Suppl 6A):93–100, 1991
29. Cole P, Wilson R: Host-microbial interrelationships in respiratory infection. Chest 95(suppl):217–221, 1989
30. Cundell DR, Devalia JL, Wilks M, et al: Generation of compounds inhibiting human neutrophil migration in vitro. Am Rev Respir Dis 141:A620, 1990
31. Currie DC, Saverumuttu SH, Peters AM, et al: Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis. Lancet 1:1335–1339, 1987
32. Davies BI, Maesen FPV, Teengs JP, et al: The quinolones in chronic bronchitis. Pharmaceutisch Weekblad (Sci) 8:53–59, 1986
33. Derenne JP, Fleury J, Pariente R: Acute respiratory failure of chronic obstructive lung disease. Am Rev Respir Dis 138:1006–1033, 1988
34. Doem GV: Trend in antimicrobial susceptibility of bacterial pathogen of the respiratory tract. Am J Med 99(Suppl 6B):3–7, 1995
35. Doem GV, Brueggemann A, Holley HP Jr, et al: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 41:1208–1213, 1997
36. Doem GV, Brueggemann A, Pierce G, et al: Antibiotic resistance among clinical isolates of Hemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother 41:292–297, 1997
37. Doem GV, Brueggemann A, Pierce G, et al: Prevalence of antimicrobial resistance among 723 outpatients clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:2884–2886, 1997
38. Dorca J, Torres A: Lower respiratory tract infections in the community: Towards a more rational approach. Eur Respir J 9:1826–1831, 1993
39. Douglas RG Jr: Prophylaxis and treatment of influenza. N Engl J Med 322:443–450, 1990
40. Eller J, Ede J, Rossdeutscher W, et al: Sputum bacteriology of acute infective exacerbation: Chronic obstructive pulmonary disease versus bronchiectasis. Eur Respir J 9(suppl):107, 1996
41. Elmes PC, Fletcher CM, Dutton AAC: Prophylactic use of oxytetracycline for exacerbations of bronchitis. Br Med J 2:1272–1275, 1957
42. Elmes PC, King TKC, Langlands JHM, et al: Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 2:904–908, 1965
43. Empey DW, Laitinen LA, Jacobs L, et al: Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 113:131–138, 1976
44. Fagon J-Y, Chastre J, Trouillet J-L, et al: Characterization of the distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 142:1004–1008, 1990
45. Farley MM, Stephens DS, Mulks MH, et al: Pathogenesis of IgA1 protease-producing and non-producing Hemophilus influenzae in human nasopharyngeal organ cultures. J Infect Dis 1547:752–759, 1986
46. Fielding JE, Phenow KJ: Health effects of involuntary smoking. N Engl J Med 319:1452–1460, 1988
47. Fiscella K, Franks P: Cost-effectiveness of the transdermal nicotine patch as an adjunct to physician's smoking cessation counselling. JAMA 275:1247-1251, 1996
48. Fisher M, Akhtar AJ, Calder MA, et al: Pilot study of factors associated with exacerbations of chronic bronchitis. Br Med J 4:187-192, 1969
49. Fletcher CM, Peto R: The natural history of chronic airflow obstruction. Br Med J 1:1645-1648, 1977
50. Garibaldi RA: Epidemiology of community acquired respiratory tract infections in adults: Incidence, etiology, and impact. Am J Med 78(Suppl 6B):32-37, 1985
51. Griffith DE, Levin JI: Occupational bronchitis. In Bardana E, Montarano A, O'Hallaren M (eds): Occupational Asthma. Philadelphia, Hanley & Belfus, 1992
52. Gonzales R, Steiner JE, Sande MA: Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 278:901-904, 1997
53. Grayston JT: Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 16:757-763, 1992
54. Grayston JT, Kuo C-C, Wang SP, et al: A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 315:161-168, 1986
55. Groenewald V, van Alphen L, Eijk PP, et al: Endogenous and exogenous reinfections with Haemophilus influenzae in patients with chronic obstructive pulmonary disease: The effect of antibiotic treatment on persistence. J Infect Dis 161:512-517, 1990
56. Grossman RF, Mukerjee J, Vaughan D, et al: A one-year community based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113:131-141, 1998
57. Gump DW, Phillips CA, Forsyth BR, et al: Role of infection in chronic bronchitis. Am Rev Respir Dis 133:465-473, 1986
58. Gwaltney JM: Acute bronchitis. In Mandell, Douglas, and Bennett's: Principles and Practice of Infectious Diseases, ed 4. Edinburgh, Churchill Livingstone, 1995, pp 606-608
59. Hers JFP: Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis 93:162-171, 1966
60. Higgins MW, Enright PL, Kronmal RA, et al: Smoking and lung function in elderly men and women: The cardiovascular health study. JAMA 269:2741-2748, 1993
61. Higgins MW, Keller JB, Metzner HL: Smoking, socioeconomic status and chronic respiratory disease. Am Rev Respir Dis 116:403-410, 1977
62. Hill S, Pye A, Johnson MM, et al: A role for Haemophilus parainfluenza in chronic lung disease. Am J Respir Crit Care Med 155:A105, 1997
63. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al: Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey. Eur Respir J 9:1590-1595, 1996
64. Immunization Practices Advisory Committee: Pneumococcal polysaccharide vaccine. MMWR 38:64-68, 73-76, 1989
65. Intercontinental Medical Statistics (IMS). Ruislip, Middlesex, BPI/MDI, 1993
66. Jamal K, Cooney TP, Fleetham JA, et al: Chronic bronchitis: Correlation of morphological findings to sputum production and flow rates. Am Rev Respir Dis 129:719-722, 1984
67. Jayanthi V, Probert CSJ, Sher KS, et al: Smoking and prevention. Respir Med 85:179-183, 1991
68. Jorgensen JH: Update on mechanism and prevalence of antimicrobial resistance in Hemophilus influenzae. Clin Infect Dis 14:1119-1123, 1992
69. Kayser FH, Morenzoni G, Santanam P: The second European collaborative study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbial Infect Dis 9:810-817, 1990
70. Lebowitz MD, Burrows B: The relationship of acute respiratory illness history to the prevalence and incidence of obstructive lung disorders. Am J Epidemiol 105:544-554, 1977
71. Lindsay G, Scorer HJN, Carnegie CMD: Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomized double blind trial. J Antimicrob Chemother 30:89-100, 1992
72. Lode H: Respiratory tract infections: When is antibiotic therapy indicated? Clin Ther 13:149–156, 1991
73. Loosli CG, Stinson SF, Ryan DP, et al: The destruction of type 2 pneumocytes by airborne influenza PR8-A virus: Its effect on surfactant and lecithin content of the pneumonic lesions of mice. Chest 67(suppl):7, 1975
74. MacFarlane JT, Colville A, Guion A, et al: Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet 341:511–514, 1993
75. Matsuse T, Hayashi S, Kuwano K, et al: Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 146:177–184, 1992
76. Medical Research Council: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1:775–779, 1965
77. Medici TC, Chodosh S: The reticuloendothelial system in chronic bronchitis. Am Rev Respir Dis 105:792–804, 1972
78. Monse O, Ruiz J, Rosell A, et al: Bacteria infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152:1316–1320, 1995
79. Monto AS, Ross HW: The Tecumseh study of respiratory illness: X. Relations of acute infections to smoking, lung function and chronic symptoms. Am J Epidemiol 107:57–64, 1978
80. Morrell DC: Expressions of morbidity in general practice. Br Med J 2:454–458, 1971
81. Murphy TF, Seithi S: State of the art. Bacterial infection in chronic obstructive lung disease. Am Rev Respir Dis 146:1067–1083, 1992
82. Musher DM, Kubitschek KR, Crennan J, et al: Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med 99:444–450, 1983
83. Neu HC, Chick TW: Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 104:1393–1399, 1993
84. Newhouse M, Sanchis J, Bienstock J: Lung defense mechanisms. N Engl J Med 295:990–998, 1976
85. Nichol KL, Margolis KL, Wuorenma J, et al: The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331:778–784, 1994
86. Nicotra MB, Rivera M, Awe RJ: Antibiotic therapy of acute exacerbations of chronic bronchitis. Ann Intern Med 97:18–21, 1982
87. Niewoehner DE, Erbland ML: Systemic corticosteroids in COPD: An unresolved clinical dilemma. Chest 110:867–869, 1996
88. Orcel B, Delclaux B, Baud M, et al: Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 7:446–452, 1994
89. Paton JC, Ferrante A: Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immunol 41:1221–1216, 1983
90. Peterson ES, Esman V, Honcke P, et al: A controlled trial of the effect of treatment on chronic bronchitis: An evaluation using pulmonary function tests. Acta Med Scand 182:293–305, 1967
91. Peto R, Speizer FE, Cochrane AL, et al: The relevance in adults of airflow obstruction but not of mucous hypersecretion, to mortality from chronic lung disease. Am Rev Respir Dis 128:491–500, 1983
92. Pines A, Raafat H, Greenfield JSB, et al: Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 66:107–115, 1972
93. Proud D, Naclerio RM, Gwaltney JM, et al: Kinins are generated in nasal secretions during natural rhinovirus colds. J Infect Dis 161:120–123, 1990
94. Ras G, Wilson R, Todd H, et al: Effect of bacterial products on neutrophil migration in vitro. Thorax 45:276–280, 1990
95. Rice KL, Leatherman JW, Duane PG, et al: Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 107:305–309, 1987
96. Rodnick JE, Gude JK: The use of antibiotics in acute bronchitis and acute exacerbations of chronic bronchitis. West J Med 149:347–351, 1988
97. Saint S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273:957–960, 1995
98. Sakakura Y: Changes of mucociliary function during cold. Eur J Respir Dis 64(Suppl 128):348–354, 1983
99. Schroeckenstein DC, Busse WW: Viral "bronchitis" in childhood: Relationship to asthma and obstructive lung disease. Semin Respir Infect 3:40–48, 1988
100. Schwartz DA: Acute inhalational injury. Occup Med State Art Rev 2:297–318, 1987
101. Seneff MK, Klainer AS, Wolff M, et al: Herpetic febrile tracheobronchitis. Ann Intern Med 1:229–233, 1988
102. Smith CB, Golden CA, Kanner RE, et al: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 121:225–232, 1980
103. Stockley RA, Burnett D: Serum derived protease inhibitors and leucocyte elastase in sputum and the effect of infections. Bull Eur Physiolpathol Respir 16:579–582, 1980
104. Strom K: Survival of patients with chronic obstructive pulmonary disease receiving long-term domiciliary oxygen therapy. Am Rev Respir Dis 147:585–591, 1993
105. Tager I, Speizer FE: Role of infection in chronic bronchitis. N Engl J Med 292:563–571, 1975
106. Traver GA, Cline MG, Burrows B: Predictors of mortality in chronic obstructive pulmonary disease: A 15 year follow-up study. Am Rev Respir Dis 119:895–902, 1979
107. Turner-Warwick M, Hodson ME, Corrin B, et al: Clinical Atlas of Respiratory Diseases. London, Gower Medical Publishing, 1990
108. US Bureau of the Census: Statistical Abstract of the United States, ed 14. Washington, DC, US Bureau of the Census, 1994, p 95
109. Verheij TJM, Kaptein AA, Mulder JD: Acute bronchitis: Etiology, symptoms and treatment. J Fam Pract 6:66–69, 1989
110. Vishwanath S, Ramphal R: Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 85:197–202, 1984
111. Walsh JJ, Dietljen LF, Low FN, et al: Bronchotracheal response in human influenza. Arch Intern Med 108:98–110, 1961
112. Wilson R: Outcome predictors in bronchitis. Chest 108(suppl):53–57, 1995
113. Wilson R, Alton E, Rutman A, et al: Upper respiratory tract viral infection and mucociliary clearance. Eur J Respir Dis 70:272–279, 1987
114. Wilson R, Pitt T, Taylor G, et al: Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 79:221–229, 1987
115. Winther B, Farr B, Turner RB, et al: Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol 143(suppl):19–24, 1984
116. Woolcock AJ: Epidemiology of chronic airways disease. Chest 96(Suppl 3):302–306, 1989
117. Wynder EL, Kaufman PL, Lesser RL: A short-term follow-up study on ex-cigarette smokers: With special emphasis on persistent cough and weight gain. Am Rev Respir Dis 96:645–655, 1967
124. Xu X, Christiani DC, Dockery DW, et al: Exposure-response relationships between occupational exposures and chronic illness: A community-based study. Am Rev Respir Dis 146:413-418, 1992

125. Yoo O, Donath J, Desmond E, et al: The problem of diagnosing bacterial pneumonia in patients with chronic bronchitis: Bacteria in sputum and bronchial washings from patients with chronic bronchitis are antibody coated. Mt Sinai J Med 55:395-398, 1988

Address reprint requests to
Ronald F. Grossman, MD, FRCPC
Mount Sinai Hospital, Suite 640
600 University Avenue
Toronto, Ontario, Canada
M5G 1X5